Spinraza stabilized lung function, sleep in children with SMA types 2, 3
Treatment with Spinraza (nusinersen) for two years led to improvements in apnea and oxygen saturation during sleep in children…
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Treatment with Spinraza (nusinersen) for two years led to improvements in apnea and oxygen saturation during sleep in children…
Avenue Therapeutics has won the exclusive rights to develop and commercialize AJ201, AnnJi Pharmaceutical’s experimental treatment for…
TREAT-NMD and Aetion have formed a partnership to deliver real-world evidence and promote the development of new treatments…
A 23-day-old girl with spinal muscular atrophy (SMA) type 2, later treated with Spinraza (nusinersen), underwent successful surgical…
Disease-modifying therapies (DMTs) used for spinal muscular atrophy (SMA) may contribute to the development of therapies for age-related progressive…
Microvasculopathy — damage to small blood vessels — occurs in patients with spinal muscular atrophy (SMA) and it can…
Get regular updates to your inbox.